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Abstract
Multiple sclerosis (MS) is a highly heterogeneous disease as it can present inter-individually as well as intra-
individually, with different disease phenotypes emerging during different stages in the long-term disease course. In
addition to advanced immunological, genetic and magnetic resonance imaging (MRI) profiling of the patient, the
clinical profiling of MS patients needs to be widely implemented in clinical practice and improved by including a
greater range of relevant parameters as patient-reported outcomes. It is crucial to implement a high standard of
clinical characterization of individual patients as this is key to effective long-term observation and evaluation.
To generate reliable real-world data, individual clinical data should be collected in specific MS registries and/or
using intelligent software instruments as the Multiple Sclerosis Documentation System 3D. Computational analysis
of biological processes will play a key role in the transition to personalized MS treatment. Major breakthroughs in
the areas of bioinformatics and computational systems biology will be required to process this complex information
to enable improved personalization of treatment for MS patients.
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Background
Multiple sclerosis (MS) is a neurological disease of the
central nervous system that is characterized clinically
both by relapses caused by inflammatory demyelination
and by neurological disability caused by axonal damage
[1]. Since the first MS symptoms occur early in adulthood
and life expectancy is only mildly reduced, MS is consid-
ered a long-term disease that affects the patient for
decades [2]. MS is a highly heterogeneous disease as it can
present inter-individually as well as intra-individually, with
different disease phenotypes evident in different disease
stages, which is probably not only true for the etiology,
pathological features and immunological findings, but also
for the disease course and response to treatment [3, 4]. As
current treatments for MS mainly target the early inflam-
matory processes, the current treatment strategy is to start
treatment early to prevent neurodegeneration [5, 6]. The
need to ensure proper treatment for the patient with MS,
considering the various clinical and immunopathological
subtypes of the disease, requires clear profiling or
characterization of the individual patient, definition of
clinical criteria for responsiveness and/or treatment failure
and collection of real world data in MS patient care [7–9].
Need for data collection in MS care
During this lifelong disease, a large amount of medical
data accumulates with important information pertaining
to medical conditions, symptoms as well as diagnostic and
therapeutic measures [10]. Even with proper documenta-
tion, in individual cases the assessment of responders and
non-responders to immunomodulatory therapies is very
difficult. Certainly, in the absence of such documentation,
assessment is impossible [8, 11–13]. If one adds the
characterization of psychological symptoms (e. g. depres-
sion, fatigue) and other medical disciplines (e. g. urology,
ophthalmology, neuroradiology), the necessity for complex
and comprehensive documentation becomes clear [14].
With complex data comes the need for electronic data
processing [15, 16]. By using suitable database systems,
individual disease progressions can be documented in a
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standardized way, and all the data can be saved for rapid
and easy retrieval in a clear format. Automatic calcula-
tions lower the threshold for a systematic application of
established scales which are currently indispensable for
quantifying neurological deficits [17]. Interestingly, expert
recommendations now mandate the regular use of scales
such as the Expanded Disability Status Scale (EDSS) or the
Multiple Sclerosis Functional Composite (MSFC) [18, 19].
Despite many convincing arguments for a detailed elec-
tronic documentation of MS patients, implementation in
clinical practice remains difficult [20, 21]. One factor
behind slow adoption of scales is a lack of consistency in
how physicians are remunerated for their time spent
filling out documentation, and the lack of motivating
initiatives on the part of the institutions assuming the cost
of treatment [22]. Only in the Scandinavian countries and
in Australia have national registries have been imple-
mented with relevant governmental support [23–26].
These registries are set to to form the interface between
the national registries and the in- and outpatient records
in use in hospitals and clinics, thus making registration
easy and user-friendly for the clinician with immediate
payback to the individual physician and patient as a time-
line based graphical display on a computer screen showing
information on demographics, clinical manifestations,
genetic profile, biomarkers including CSF, MRI and treat-
ment. Development of software applications based on a
structured clinical records can harvest key information for
registries already underway [27, 28]. The pharmaceutical
industry has developed various electronic documentation
systems which, after an appropriate pilot phase, have not
been further pursued [13, 29]. Looking behind the reasons
for this failure, it becomes apparent that a documentation
platform that is dependent upon a single pharmaceutical
manufacturer is does not have widespread traction. To
date, MS Base is the only independent initiative in MS
that has survived transfer from a pharmaceutical company
to the public domain [30].
At present, major sources of MS big data, including
clinical registries, electronic health record data and admin-
istrative databases (for example, claims for services and
pharmaceuticals) chiefly contain classical clinical parame-
ters for evaluation of MS. As time moves forward, more
data are available from sophisticated sources such as
medical imaging, biomarkers, and other ‘omics.’ Modern
technologies, including wearable devices are also able to
generate data, as are internet resources such as social
media web sites.
Clinical profiling of MS patients
An increased understanding of MS and its pathology,
together with general concern that these descriptors may
no longer adequately reflect recently identified clinical
aspects of the disease, prompted a re-examination of MS
disease phenotypes [31]. Some clinical manifestations may
be too subtle to detect easily no matter how frequently
they are assessed [32]. Following patients closely for
cognitive, visual, and other clinical changes could provide
clinical evidence for disease activity, functionality and
clinical disability [33, 34].
The Multiple Sclerosis Performance Test (MSPT) is a
computer-based platform for precise, valid measurement
of MS severity [35]. Based upon and extending the MSFC,
the MSPT provides precise, quantitative data on walking
speed, balance, manual dexterity, visual function, and
cognitive processing speed.
Our software MSDS3D implements the two-dimensional
functional disability scale (2D FDS), which comprises
clinical and subclinical measures representing perspectives
from both the patient and the physician (Fig. 1) [36]. Since
deterioration not only occurs in the motor, visual, and
sensory systems, this scale additionally includes cognitive
changes, mood swings, fatigue, bowel and bladder function,
sexual dysfunction, quality of life, as well as work product-
ivity and activity. The overall aim is to obtain a compre-
hensive picture of the patient’s disease status. All the
measures listed are integrated into our ‘state of the art’
evaluation of patient status.
Consensus is lacking regarding the use of patient-
reported outcomes (PRO) and whether they are useful
indicators of disease status [37]. Tools for the remote
assessment of patient performance outside of clinical
settings may prove useful in better understanding PRO –
certainly, more correlative research in this area would be
useful [38–42]. Ease of administration has increased with
the availability of electronic PRO data collection software
and web-based data entry options, allowing for immediate
scoring that can be displayed for review during clinical
encounters [43]. Several studies demonstrate that elec-
tronic data collection is preferred in clinical care compared
to paper-based approaches [44–46]. Reproducibility of
electronic data collection and responder rates are high,
which reduces instances of missing data [47, 48]. Modern
systems can also provide a consistent look for all content
administered to patients. One of the reasons for success of
this approach in clinical research has been computerized
adaptive testing whereby the software selects questions on
the basis of a person’s response to previously administered
queries, tailoring a questionnaire with a minimal number
of questions (high precision and wide-range method) [46].
Data collected using these approaches can be quite compli-
cated to analyse and can be difficult to manage in practice,;
however, first steps have been taken towards implementa-
tion into clinical practice [49]. It is worth mentioning that
specific guidelines do not yet exist for the selection and
application of PRO measures in MS clinical practice, and
neither are these questionnaires part of a wider medical
software applications.
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High quality clinical profiling is prerequisite to understand
individual disease courses and treatment responses (Fig. 2).
Additional parameters to be collected alongside clinical
parameters
During the last decades, establishing satisfactory bio-
markers for multiple sclerosis has been very difficult due to
the clinical and pathophysiological complexities of the dis-
ease [50]. The emergence of immunogenetics, neuroimmu-
nology and neuroimaging, means that detailed clinical
profiling ought be complemented by assessment of poten-
tial biomarkers to inform decision making concerning stra-
tegic and individualized therapeutics [51]. However, with
some exceptions, many biomarkers evaluated thus far have
yet to be shown to have useful prognostic capability. The
the only way to investigate their prognostic role is to com-
bine these data on biomarkers with detailed clinical moni-
toring data in MS registries [25, 52]. Regardless of data
type, all parameters collected as an adjunct clinical profiling
depend on the quality of the medical documentation, and
their quality is critical of they are to corellated with labora-
tory and imaging data. The availability of reliable bio-
markers could radically alter our management of MS at
critical phases of the disease spectrum. Identification of
markers that could predict the development of MS in high-
risk populations would allow for intervention strategies that
may prevent evolution to established disease [53].
MS registries as tool to collect real world data
Most studies, in particular those concerning the therapeutic
effect of immunomodulatory therapies, usually occur over
of 2 – 3 years of follow-up [54]. This is counter to the
disease course of MS, which runs over several decades. In
order to reveal long-term aspects of the disease, so-called
register studies for MS patients were initiated some time
ago with the goal to provide valuable information pertain-
ing to prevalence, current therapy pattern and disease
Fig. 1 Two-dimensional functional disability scale (2D FDS) including clinical and subclinical measures representing both the patient’s and the
physician’s perspectives in MSDS3D
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progression data [55, 56]. Such data can be collected over
long periods of time, for example, more than 20 years [57].
These MS registers enable correlations of disease
progression with demographic and clinical characteristics
[58]. Consequently, register studies can provide data on the
long-term progression of MS, wish is information urgently
needed by the clinical community. Of course, MS registers
have their limitations, in particular concerning the
generalizability of the data [55]. A MS register only allows
conclusions to be drawn for the cohort of patients
documented within the scope of the register [26].
MS registers can be physician-oriented or patient-
oriented with different advantages and disadvantages in
each case [26, 30, 59]. The clear advantage of physician-
centered registers is the detailed clinical and demographic
documentation. However, the disadvantage is the high
documentation effort from the physician’s side, which
makes a long-term documentation of large cohorts diffi-
cult. Patient-based registers allow the collection of data
from large patient numbers and they are relatively cost-
effective [59]. However, the lack of medical screening as
well as data validation by a physician can lead to significant
errors (for example a missing MS diagnosis). Despite these
problems, there are patient-centered MS registers with high
response rates and 90 % or more correct MS diagnoses.
Observations of register studies are particularly valu-
able and clinically relevant if several register studies can
confirm their findings reciprocally. However, it is
important to note that real world data for different co-
horts are different, and this can make correlations of this
type difficult [60]. Each database is unique and usually
emphasizes different features. Altogether, a lack of
consistency is mostly related to quantitative and qualita-
tive differences in data collection [54].
MS registers are the only meaningful opportunity to
collect long-term data – these data cannot be collected by
other means because it is not possible to track such a large
number of patients over such a long time period within
the scope of a clinical study. Methodologically, a prospect-
ive, standardized data collection like this overcomes the
limitations in statistical power that characterize most clin-
ical studies [56]. Nevertheless, these register databases are
widely criticized for their lack of statistical power relating
to poor associations and the prediction of rare events as
well as their incompleteness. In addition, guaranteeing
high data quality is a huge challenge, particularly when
there are limited financial resources.
MSDS 3D – combining documentation and management
of MS
Since 2008 the eHealth / MSDS3D project group in
Dresden has been developing the patient management
system Multiple Sclerosis Documentation System (MSDS)
3D, which is a new development of MSDS Klinik in
practice throughout Germany [16]. Due to ever more
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Fig. 2 Combining individual treatment and big data RWE approach as a combined treatment approach: Individual clinical profiling is essential to
characterize the individual patient in detail which is essential for individual treatment decisions. On the other side, collecting all individual
patients profiles using big data approach can predict disease course and treatment responses again making personalized medicine possible
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innovations over the last years, this is an attempt to go a
step further and provide not only a patient documentation
system but also an electronically supported adaptive
patient management system for multiple sclerosis [13, 61].
In highly specialized diseases such as MS, a specific, intelli-
gent management system, which goes beyond a mere MS
documentation, is needed by all parties involved in the
treatment process [38, 62]. For prospective data collec-
tions, eg. innovative drug-specific phase IV trials, a simple
documentation system that does not support the user with
prospective data entry, or that does not remind him if im-
portant data are missing is not adequate [36, 63–65].
The entire process for the MSDS3D system includes the
patient, nurse and physician in the system. Furthermore,
the system can be used both for the collection and inter-
pretation of patient data, and for conveying information to
the patient interactively. Interaction with the patient takes
place either via online multi-touch systems, such as a
touchscreen or a touchpad as an interactive patient ter-
minal, or via mobile devices such as smartphones (Fig. 3a).
The interview system for the questionnaire-based data col-
lection integrated into MSDS3D is equipped with a user
interface that was specifically designed for MS patients [44,
45]. In addition, the medical staff manages the process of
the interview (for example the start of the interview) and
provides any necessary assistance with answering. Mobile
devices are controlled by the MSDS3D system located in
the local treatment center via a specific server that also
controls the data flow to and from the patient. Anonymity
and data protection are guaranteed by a complex process
that includes an encrypted transmission. An expert advice
system is included in the software to enable specialists
involved in special cases to provide their opinion [64].
Neurologists who make use of clinical expert advice at any
time during the study and radiologists seeking an MRI sec-
ond opinion reading are asked to document these requests.
MSDS3D is a module-based, web-based or locally-
installed software which is connected to a single central
database (Fig. 3b). Different modules for the various MS
treatments are implemented in the software to assist drug-
specific management and to collect drug-specific observa-
tional data.
For each treatment, the individual MSDS3D module
allows for standardized documentation and visualization of
appointment schedules and the patient examinations by
structuring the information on a vertical timeline with hori-
zontally arranged tasks that are displayed as tick boxes. Each
tick box related to a parameter that must be collected at a
given time point. The corresponding data input menu can
be opened directly from these tick boxes, and additional
procedures can be added to a selected visit. Above the task
box that documents the current visit of the patient, the next
appointment is displayed with the planned timeframe; below
this, the user can scroll through the historical completed
visits. The respective tasks that have to be implemented
(such as EDSS, patient interview) are displayed in by way of
separate instruments [13]. Different color codes assist in
monitoring the status of each task box: Green color indi-
cates that a task has been completed by the MS nurse (e.g.
patient questionnaire, cognitive tests) or the treating neur-
ologist (e.g. EDSS, adverse effects). When all tasks of a visit
have been completed, the visit is set as ‘approved’.
All data management processes will be overseen by an
external data management team, which is extremely
important to improve data quality and validity. Addition-
ally, a toolbar allows for the integration of administrative
features (such as creating a patient record, registering
a patient for an examination) and of evaluation mech-
anisms into the patient management system MSDS3D.
Data can be exported to various databases, an internal
query process is part of MSDS3D.
An important part of MSDS3D is the safety reporting
and monitoring procedures. As MSDS3D is used for
phase IV studies, an easy-to-use safety reporting system
is included, which is not generally seen in other observa-
tional registry initiatives.
Clinical profiling of MS patients and data collection for
MS big data
All these technological approaches can be extremely useful
to clinicians, providing a global, easy-to-access perspective
of the disease that adds value to clinical practice: they can
provide graphical representations of patients’ course, they
allow benchmarking, they help to create better decision
strategies and, since they collect data from large popula-
tions, they can also be used for a large number of studies
(e.g. comparative drug effectiveness, pregnancy exposure
outcomes, safety registries and long-term disease trends) In
this way, computerized MS registries are set to form part of
the future MS cloud computing and big data (Fig. 4).
Big data analysis in MS: challenges and problems
Computational analysis of biological processes plays a
key role in the transition to personalized MS treatment.
According Miller et al. the following specific contribu-
tions of information technology to tailored therapy are
crucial:
(1) the ability to integrate genomic, molecular, and
epigenetic data about each individual patient in a
unified framework,
(2) the capability to effectively analyze this information
using complex queries and data mining methods,
and
(3) to apply computational procedures that predict the
patient’s response to treatment based on his or her
genomic make-up, epigenetic tendencies, and
environmental data [9].
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Fig. 3 a MSDS3D as interdisciplinary platform to manage MS patients using the MSDS3D cloud connected with devices (b) MSDS3D as both
local and web-based data entry system using module- and task box based technology and the MS overview
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Big data analysis in MS raises several methodological
issues that need to be addressed to succeed in clinical
practice. Major points include the limitations of observa-
tional data, poor data quality, data inconsistency, poor
data stability, patient privacy, patient consent, and other
potential legal barriers. Many data sources have signifi-
cant quality limitations. The results can be valid, stable,
and clinically useful only if high-quality clinical data are
inputted. A related issue is the lack of documentation
standards in MS care, which exacerbates the inconsist-
ency in different data sources. The potential threats to
the validity of real world data from observational studies
include both unmeasured confounding factors and
treatment selection bias. Legal and regulatory aspects
(inadvertent release of private patient healthcare data,
inappropriate access to or use of patient data, and
even the potential use of data to inappropriately
‘profile’ patients and provide differentiated healthcare
resources) also have a negative impact on successful
implementation [66]. Last but not least, big data
approaches will require clinical integration to be
successful, facing the same implementation challenges
as other healthcare quality interventions that require
integration into the clinical workflow to achieve
clinical utility [67].
Predictive models are used to inform physicians about
a patient’s absolute risk of developing a defined clinical
outcome and to guide patient management [68]. A
predictive model includes characteristics that are















Fig. 4 Profiling patients and collecting data. As part of the personalized medicine approach, MS patients should be characterized by a detailed
clinical profiling which is the base of all long-term documentation. All patients should be documented during the course of the disease to
understand treatment response, document relapses and disease progression as well as quantitative inflammatory and neurodegenerative
magnetic resonance imaging (MRI) markers. Physician- and patient-centered parameters should be collected by intelligent software systems
as MSDS software. MS big data can be used to analyze treatment response patterns and allow personalized treatments. Therefore, the available
information (big data MS) of all included MS patients can assist in complex treatment decisions in future
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necessarily causal in the disease process. In the trad-
itional physician-patient interaction, the patient provides
the physician with the data which are necessary for
evaluation. Using predictive modelling, the patient
provides data to the physician who incorporates it into a
decision support algorithm for diagnosis or treatment
(or the patients generate and submit their own data into
the predictive algorithm), allowing the physician to
receive clinical insights in real time (Fig. 5).
Conclusions
MS is multifactorial, and therefore requires the capability
to model and analyze the interplay among the wide range
of parameters that are involved in the onset of the disease,
its progression, and the response to treatment. In addition,
machine learning methods have been employed to profile
MS patient gene expression response to interferon-beta
[69]. To truly personalize treatment of MS, major break-
throughs in the areas of bioinformatics and biological
computation systems will be required to make sense of
this large and complex mix of information types.
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